glp 1 pancreatic cancer GLP-1 Risk: What New Data Reveal Frontiers | The Intricate Crosstalk
Description
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al
Obesity (Silver Spring, Md)
On average, patients return to their pre-treatment weight within 1.7 years of stopping any weight management medication, including semaglutide and tirzepatide
The only GLP-1 medication that is FDA-approved to treat sleep apnea is Zepbound
